ClinicalTrials.gg
CompletedNCT06203444Updated Jul 11, 2024

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

A Phase 1 interventional study of Tenapanor in Lactation, sponsored by Ardelyx. Completed at 2 sites in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Ardelyx · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Breast Feeding with a site in United States — 44 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.

Enrollment
180th of 202
7 · median 83
Started
2023
with 12 others
Phase 1
8 of 251
2 open now
Registered
208th of 251
by date

Among the 251 studies in Breast Feeding with a site in United States, this one is the 180th largest by enrollment of the 202 interventional ones that give a count, is one of 13 that started in 2023, is one of 8 in phase 1, and was the 208th registered.

Breast Feeding

1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.

Browse Breast Feeding studies →

Open to participants now

44 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.

This study: 18 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Breast Feeding with a site in United States, or all of them as a file.
02

Study summary

This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.

Read the detailed description

This will be an open-label study to investigate the PK of tenapanor and AZ13792925 in breast milk of lactating female subjects. Potential subjects will be screened to assess their eligibility to enter the study within 15 days prior to the first dose administration. Subjects will receive tenapanor from Days 1 to 4 and will be monitored for 24 hours after the last dose of tenapanor. On Day 4, breast milk to evaluate concentrations of tenapanor and AZ13792925 will be collected pre-dose (Hour 0), 1, 2, 4, 6, 8, and 24 hours post-dose. Subjects will return for a Follow-up visit, 5 to 7 days (Day 10±1) after the last dose. All breast milk not used for PK analyses will be discarded (not fed to infant) starting on Day 1 after the first dose of tenapanor is administered until Day 7 (72 hours after last dose of tenapanor).

03

Conditions studied

  • Lactation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must satisfy all of the following criteria at the Screening visit unless otherwise stated:

    1. Females greater than or equal to 18 years of age.
    2. between 18.0 and 35.0 kg/m2, inclusive.
    3. In good health with no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory as determined by the Investigator.
    4. Females must be non-pregnant.
    5. Has been breastfeeding or actively pumping for at least 4 weeks.
    6. Willing to continue regular pumping in order to maintain milk supply for the duration of the study.
    7. Will not feed infant breast milk while taking tenapanor and for 72 hours post the last dose of tenapanor.
    8. Weaning must not be underway, to ensure an adequate milk supply.
    9. Able to comprehend and willing to sign an ICF and to abide by the study restrictions

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:

  1. Significant medical or psychiatric disorder, as determined by the Investigator that would interfere with participation.
  2. Use or intend to use any prescription or non-prescription medications 4 days before first dose of tenapanor until Day 6 of the study, unless deemed acceptable by the Investigator and/or Sponsor.
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
  4. Has mastitis or other condition that would prevent the collection of milk from one or both breasts.
  5. Loose stools (Type 6 or 7 on the Bristol Stool Form Scale) ≥2 days in the past 7 days
  6. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days prior to dosing or 5 half-lives prior to dosing.
  7. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Eligible subjects will be enrolled to receive the study drug

    Drug: Tenapanor

Interventions

  • The study drug will be administered in dose of 50 mg bid

    Also known as: IBSRELA

06

What researchers measure

Primary outcomes

  1. Concentration of tenapanor and its major metabolite in breast milk

    The primary objective of the study is to determine the maximum observed milk concentration (Cmax) of tenapanor and its primary metabolite AZ13792925 in the breast milk of lactating female subjects.

    Time frame: 26 Days

Secondary outcomes

  1. The safety of tenapanor in lactating females

    The secondary objective of the study is to assess the the incidence and severity of treatment-emergent adverse events of tenapanor when administered to lactating female subjects.

    Time frame: 26 Days

07

Study locations

2 sites
  • DDSI
    Oklahoma City, Oklahoma 73112, United States
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in May 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2023
First posted
Jan 12, 2024
StartActual
Nov 27, 2023
Primary completionActual
May 30, 2024
CompletionActual
May 30, 2024
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06203444
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Nov 27, 2023
Primary completion
May 30, 2024
Completion
May 30, 2024
Last update
Jul 11, 2024

Study contacts

Susan Edelstein, PhD
study director · Ardelyx

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion